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Clinical relevance 
 
Clinical guidelines suggest that patients with oral lichen planus should improve their 
oral hygiene.  Systematic reviews have suggested that patient-centered outcome 
measures be used in oral lichen planus outcome studies. 
 
Principal findings 
 
A structured plaque control intervention was more effective than control in 
improving the oral health related quality of life for subjects with gingival oral lichen 
planus. 
 
Practical implications 
 
This study provides support to the existing clinical guidelines that recommend 
optimizing oral hygiene for patients with oral lichen planus.  Structured plaque 
control should form part of the first line treatment for patients presenting with 
gingival lesions. 
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The impact of structured plaque control for 
patients with gingival manifestations of oral 
lichen planus: a randomized controlled study 
 
Abstract 
 
Aim:  To evaluate the impact of a structured plaque control intervention on 
clinical and patient-centered outcomes for patients with gingival manifestations 
of oral lichen planus. 
Materials and methods:  Eighty-two patients were recruited into a 20-week 
randomised controlled trial.  The intervention was structured plaque control 
comprising powered tooth brushing and inter-dental cleaning advice.  Control 
subjects continued with their normal dental plaque control regimen.  The 
primary outcome measure was the oral health impact profile (OHIP) with 
secondary outcomes of pain, plaque index, mucosal disease score and cost-
effectiveness. 
Results: Overall the intervention patients showed statistically significant 
improvements in OHIP sum ordinal and dichotomous scores compared with 
control.  There were improvements in the functional limitation, psychological 
discomfort and physical disability domains at 4- and 20-weeks and in the 
psychological disability domain at 20-weeks.  The intervention was successful in 
reducing plaque compared to control (p<0.001) and improvements were 
observed using the mucosal disease indices at the 4- and 20-week follow ups 
(p<0.001). 
Conclusion 
A structured plaque control intervention was effective in improving the oral 
health related quality of life and clinically observed gingival lesions.  This study 
provides evidence to include intensive plaque control within patients’ initial and 
on-going management.   
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Introduction 
 
Gingival manifestations are commonly seen in the erosive, ulcerative and 
atrophic forms of oral lichen planus (OLP) (Jadinski and Shklar, 1976, Scully and 
Porter, 1997, Leao et al., 2008, Lo Russo et al., 2009).   The lesions vary in extent 
and severity from mild localized patches to widespread intense erythema and 
ulceration with areas of spontaneous haemorrhage (Scully and Porter, 1997).  
The symptomatology of milder presentations may include sensitivity to spicy or 
acidic foods or discomfort with particular dentifrices.  The more severe 
presentations of the disease are likely to be symptomatic, painful and have 
significant impact on patients’ lives (Cheng et al., 2012).  Interventions are 
generally initiated based on controlling symptoms; the current recommended 
clinical pathway suggests that following diagnosis, initial treatment should focus 
upon controlling oral hygiene, avoid precipitating factors (e.g. drugs, foods, 
chemicals) and provide reassurance (Lodi et al., 2005, Thongprasom et al., 2003, 
Thongprasom et al., 2011).  Improving plaque control as a conservative strategy 
has been the subject of increasing interest, but there remains limited evidence 
for the effectiveness of this intervention and, as a result, topical corticosteroids 
remain the first line treatment (BSOM, 2010, Holmstrup et al., 1990, Lo Russo et 
al., 2008, Guiglia et al., 2007, Lopez-Jornet and Camacho-Alonso, 2010, Salgado et 
al., 2013).   
It is important for clinicians to understand the disease from the patient’s 
perspective so that treatments are proportionate to the reported symptoms.  
Pain scores are easy to administer and may provide some insight, but they do not 
capture other symptoms, which might be more pertinent.  These might include 
challenges with eating, in particular avoiding particular foods that may 
exacerbate symptoms, chronic soreness, frequency of ulcers, aching, general 
discomfort or even changes in mood.  Over the last 20 years there has been a 
shift to understand the effect that diseases impact upon patients’ lives.  The 
rationale being that newly developed treatment strategies should address the 
issues that are important to patients. Patient-based outcome measures have 
been developed to measure the consequences of impaired oral health from the 
patient’s perspective, frequently referred to as oral health related quality of life.  
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These instruments have been subsequently evaluated for reliability and 
consistency and are frequently used in clinical studies as primary or secondary 
outcome measures.  Rarely have patient-based outcome measures been used to 
evaluate interventions for oro-mucosal diseases including OLP, and those that 
do, generally use it as a secondary outcome measure (Hegarty et al., 2002, 
McGrath et al., 2003, Gorouhi et al., 2007, Lopez-Jornet et al., 2009, Riordain and 
McCreary, 2010, Salgado et al., 2013). It has been recommended that future 
evaluations should include pain symptoms, report adverse effects of treatment 
and include cost-effectiveness with lengthy follow-up periods to evaluate long-
term benefit (Lodi et al., 2012).  In this paper we report outcomes from a 20-
week randomized controlled trial evaluating the impact of plaque control on 
gingival oral lichen planus from the patient’s perspective.  
 
 
Aim 
 
To evaluate the impact of a structured plaque control intervention on clinical and 
patient-centered outcomes for patients with gingival manifestations of oral 
lichen planus. 
 
Methods 
 
Study design 
 
The study was conducted at Newcastle Dental Hospital, UK in accordance with 
ICH good clinical practice (GCP) between February 2011 and May 2012, a 
favourable ethical opinion was provided by Sunderland Research Ethics 
Committee, UK (Ref. 10/H0904/48).  The design, (study overview, sample size, 
recruitment, randomisation and examiner calibration) has previously been 
described (Stone et al., 2013).   
Briefly: a parallel group, longitudinal randomized controlled trial (RCT) was 
conducted to evaluate the effectiveness of a structured plaque control 
programme.  Inclusion criteria were: adult patients aged 18 years and above; 
willing and able to complete questionnaires; able to provide consent, newly 
referred or under review at Newcastle Dental Hospital with a provisional 
diagnosis of OLP with clinical signs of gingival involvement.  Exclusion criteria 
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were: unable to attend for the additional appointments prior to biopsy; unable to 
complete questionnaires (large print format were made available for those with 
visual impairment, alternatively questionnaires would be read by a researcher); 
involved in a research study within the previous 28 days.  All subjects whose 
diagnosis of OLP was not previously confirmed by biopsy and histopathological 
analysis had this performed along with direct immunofluorescence and blood 
tests where appropriate (BSOM, 2010). The intervention group received 
structured oral hygiene instruction using a powered toothbrush, Sonicare 
FlexCare+ HX6942/20 (Philips Oral Healthcare Inc.  Bothell, WA, USA) with 
interdental cleaning aids, either appropriately sized TePe® extra soft interdental 
brushes (TePe Munhygienprodukter, Sweden) ranging from ISO size 1-6 or Oral-
B dental floss (Procter & Gamble, UK).  All products were provided for the 
complete duration of the study along with standardised toothpaste for all 
subjects (Pronamel®, GlaxoSmithKline, Brentford, Middlesex, UK).  The control 
group was asked to continue with their normal plaque control regimen and did 
not receive this additional intervention or advice.  Follow up was carried out at 4 
and 20 weeks, compliance was not formally recorded. Clinical record forms were 
coded and anonymised, each participant was assigned a study number, 
participant information was kept confidential and individual subject records 
contained only sufficient data to allow identification of the participants 
throughout the study. 
Oral health-related quality of life was the primary outcome measure in this 
study. It was measured using the 49-item version of the Oral Health Impact 
Profile (OHIP-49), which has been shown to be reliable, valid and responsive to 
clinical change (Locker and Allen, 2002).  Participants were asked to rate each of 
the responses on a 5-point Likert scale. Responses were coded 0 (never), 1 
(hardly ever), 2 (occasionally), 3 (fairly often), and 4 (very often).  The OHIP was 
self-administered but checked for completeness to ensure no missing data points 
(Guyatt et al., 1993).  The questionnaire items provide information about the 
frequency (burden) by which participants had experienced specific impacts in 
the month preceding completion of the questionnaire; OHIP does not aim to 
measure severity.  Short reference periods have been used with OHIP 
successfully in the past (Sutinen et al., 2007) and in clinical trials (Allen et al., 
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2001), therefore a 4-week reference period was used at all appointments to 
allow evaluation of change over the course of the study.  Secondary outcomes 
included visual analogue scales for pain, global transition scores and validated 
clinical indices for mucosal disease and plaque control along with evaluation of 
cost-effectiveness (Silness and Löe, 1964, Slade and Spencer, 1994, Stone et al., 
2013, Escudier et al., 2007).  The data for the secondary outcomes have been 
previously reported with the exception of global change scores (Stone et al., 
2013).  These were included at each follow-up visit to provide some overall 
context to the subjects’ symptoms and also to provide validity to the OHIP data. 
 
Analytic plan 
The primary outcome measure for this study was overall sum OHIP score and by 
domain.  No weightings were to be applied to the OHIP data, sum OHIP data were 
used (Allen and Locker, 1997).   Overall sum OHIP (ordinal) data were used in 
statistical analysis to examine both intervention and control groups, ordinal data 
were used to examine each OHIP domain.  Data was also dichotomised by grouping 
subjects reporting items frequently often or very often (coded 1), and those 
reporting items occasionally, hardly ever and never (coded 0).  These data were 
summarised and analysed to further differentiate negative impacts on quality of life 
for intervention and control subjects. 
Descriptive statistics were produced for each of the primary and secondary 
outcomes according to treatment received.  Statistical analysis of the data 
including parameter and 95% confidence interval (CI) estimation was 
accomplished using SAS software.  For age and gender, continuous variables p-
values were calculated by t-test and chi-squared for categorical variables.  
Comparisons for the primary outcome measure, OHIP and clinical parameters 
between treatment groups were performed using ANOVA for baseline and 
ANCOVA for the 4-week and 20-week follow-ups. The p-values are based on a 
mixed model F-test (H0=both intervention and control treatments equal).  The 
population to be analysed comprised all randomised subjects with a baseline and at 
least one post-baseline OHIP evaluation, those without were excluded from the 
analysis.  Minor differences to those previously reported may exist based on the way 
in which those with missing data points were handled.  Global change scores were 
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calculated and analysed using Mann Whitney U statistic, assuming an abnormal 
distribution. 
 
Results 
Recruitment for the study ran from February 2011 to June 2012.  120 patients 
were invited to participate, 82 accepted, were enrolled and randomised, (39 
intervention and 43 control subjects).  3 intervention and 2 control subjects 
were lost to follow up.  One subject failed to attend visit 2 but was retained 
through to visit 3. 79 of the 82 participants data were analysed. 
The mean age for all randomised subjects was 61.4 years at the time of 
enrolment; the gender balance of 18.3% males to 81.7% females reflected the 
greater number of females with oral lichen planus in the wider population.  The 
numbers of subjects taking concomitant topical steroid medication was evenly 
distributed in both control and intervention groups (n=23).   Three participants 
were taking concomitant systemic steroids (prednisolone); two in the 
intervention group and one in the control group.  Recruitment selection bias was 
not considered to be significant. 
A summary of the baseline and follow-up OHIP data is presented in Table 1. 
There were no significant differences between the groups in baseline 
demographics or for any other parameter at baseline (p>0.05).  The groups had 
similar baseline mean OHIP sum scores 49.66 (ordinal) and 6.55 (dichotomous) 
for the intervention group and 49.39 (ordinal) and 6.71 (dichotomous) for the 
control group.  At week 4 and week 20 the distributions shift with both groups 
showed a reduction in OHIP ordinal scores overall.  The shift for the intervention 
group was more than the control group.  Both groups contained subjects who 
experienced net negative change (post-baseline minus baseline) in OHIP ordinal 
and dichotomous scores.  The negative net change in ordinal scores indicated 
subjects experiencing an overall improvement in given domain, taking into 
account both the improvement and deterioration to individual statements.  
Negative net change in dichotomous scores indicates an overall decrease in the 
impacts that happened “fairly often” or “very often” from baseline, taking into 
account some impacts happened more frequently, and some happened less 
frequently.  The intervention group experienced greater negative net change in 
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both ordinal and dichotomous scores indicating improvements in oral health 
related quality of life these differences were statistically significant at the 4-week 
(p=0.022) and 20-week (p=0.004) follow-up. 
Evaluation of the individual domain scores provides further insight into the 
range of impacts that oral lichen planus has on a subject’s quality of life.  
Statistical output for each domain was undertaken using ordinal data and 
presented in Table 1. 
Those domains with significant differences between the intervention and control 
groups at 4 and 20 weeks respectively were functional limitation (p=0.022; 
p=0.014), psychological discomfort (p=0.007; p=0.002) and physical disability 
(p=0.014; p=0.004).  The psychological disability domain showed significant 
differences at the 20-week (p=0.003) but not at the 4-week follow up (p=0.435).  
There were no significant correlations in the social disability (p=0.763; p=0.811) 
and handicap domains (p=0.858; p=0.224) at either time point and a constant 
although not statistically significant effect was observed in the physical pain 
domain (p=0.059, p=0.052). 
 
Global change 
Global change scores, recorded on a 5-point Likert scale, were coded positively 
for improvements and negatively for deteriorations in symptoms:  Improved a 
lot (2), improved slightly (1), stayed the same (0), become slightly worse (-1), 
become a lot worse (-2).  Results are displayed in Table 2.  At week 4 the mean 
global change with 95% CI was 1.03 (0.86, 1.38) for the intervention group 
indicating that the subjects in that group felt that their symptoms improved 
slightly.  The control group still showed a positive mean global score [0.26 (-0.02, 
0.53)] and there were statistically significant differences between the two groups 
(p<0.001) at the 4-week follow-up.   At the 20-week follow-up the difference in 
improvements between the groups from the 4-week time point was not 
statistically significant (p=0.067) suggesting that the greatest effect came in the 
intervention group in the time initially following the intervention.  
Effect sizes 
The effect of treatment was examined using Cohen’s d (Table 3).  Interpretation 
of effect sizes differs but it is generally agreed that those values above 0.2 are 
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seen to be having a small treatment effect, above 0.5 to have a moderate effect 
and above 0.8 to have a large effect. 
Moderate treatment effects were seen in the intervention group for OHIP ordinal 
scores at week 4 (0.61) and week 20 (0.74).  Moderate treatment effects were 
also observed in the intervention group for pain (VAS) both at the 4-week (0.52) 
and 20 weeks (0.70).  Large effect sizes were observed in the interventions group 
for PI at week 4 (1.47) and week 20 (1.56).  A moderate effect was seen in 
Escuder’s oro-mucosal disease index at week 4  (0.75) and a large effect at week 
20 (1.01).  Small changes were observed for the control group in OHIP scores and 
VAS scores at 4 and 20 weeks.  No effect was observed in PI for the control group 
at any time point.  These can be used alongside the surrogate measures of health 
(clinical indices) and subjective measures of health (OHIP) in an attempt to 
provide comprehensive assessment of the effect of the intervention.   
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Discussion 
 
The evaluation of the effectiveness of a structured plaque control programme 
used tools that were both objective and subjective measures of health and 
disease.  For context, clinical evaluation of the intervention was based on Plaque 
Index (Silness and Löe, 1964) and the Escudier index (Escudier et al., 2007).  In 
this study the mean Plaque Index scores reduced for the intervention group by 
39.5% at the 20-week follow up compared to a marginal improvement of 4.1% 
control group.  The intervention was, therefore successful in reducing plaque 
compared to control and was sustained to the end of the study at 20 weeks 
(p<0.001).  Clinical improvements were observed using the Escudier indices at 
the 4- and 20-week follow up (p<0.001). 
The mean OHIP ordinal scores at baseline were 49.7 for the intervention and 
49.4 for the control group.  In the original validation studies for OHIP involving 
older adults, the mean sum OHIP ordinal score was 31.5 (Slade, 1998).  The 
subjects with gingival manifestations of oral lichen planus in this study reported 
more frequent impacts at baseline indicating poorer oral health related quality of 
life.   It is important though to examine the individual domains to determine the 
social impact of the disease.  The physical pain domain in OHIP contains 
statements that relate to the frequency that subjects experienced painful gums, 
sore spots and discomfort when eating.  These symptoms are commonly 
reported in outpatient clinical settings therefore, it is reasonable to assume that 
this domain would have the potential for change.  Although improvements in the 
domain score were observed, they were not statistically significant from the 
control group (p>0.05). The VAS scores for pain were also not statistically 
different at the 4- and 20- week follow up (p>0.05).  Pain might therefore not be 
significantly affected by the intervention or perhaps the symptoms that have the 
greatest effect on quality of life do not include pain.  In the functional limitation 
domain there were significant differences between the control and intervention 
groups (p=0.012, p=0.014).  This domain contains statements relating to 
appearance, difficulty chewing, taste and digestion.  It may be that improvements 
in clinical signs of inflammation then bring about these secondary outcomes 
measured in this and other domains.  The largest differences between groups 
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were observed with the psychological discomfort and physical disability 
domains.  The psychological discomfort domain relates to being worried, self-
conscious, miserable, concerned about appearance and tension.  Perhaps the 
intervention is, by resolving inflammation, reducing symptoms, so that subjects 
are consequently being less concerned about their oral health.  There may also 
be some positive effect by which participating in the study affects this domain; 
particularly a study that monitors subjects more frequently than through their 
conventional clinical pathway.  This may be particularly important when 
examining a cohort of patients with a potentially pre-malignant diagnosis 
(Holmstrup, 2010).  Within the physical disability OHIP domain, which contains 
statements relating to being unable to brush teeth, avoidance of eating and 
unsatisfactory diet, there were statistical differences between the groups in 
favour of the intervention group at week 20 (p=0.004).  It is impossible to tell, 
without further adjunctive qualitative interviewing, which part of the 
intervention was the most important: the advice and reassurance, or the 
provision of appropriate aids that facilitate the perceived improvements in this 
domain.  Comparatively few impacts were observed in the final three domains: 
psychological disability, social disability and handicap.  This suggests that oral 
lichen planus does not have large disabling effects but carries significant 
psychological impact associated with the diagnosis and chronic discomfort.  
Anxiety has previously been strongly associated with the initiation of oral lichen 
planus and frequent observation and monitoring during a clinical study may go 
some way to alleviating this anxiety (Vallejo et al., 2001) 
 
Studies have suggested that painful atrophic mucosa may discourage patients 
from brushing effectively, additionally it has been reported that powered tooth 
brushing can cause minor gingival abrasions (Erpenstein, 1985, Robinson et al., 
2005).  The intervention therefore had the potential to exacerbate the lesions 
particularly with the friable, atrophic nature of the gingival tissue.  It has been 
suggested that plaque removal would potentiate new lesions resulting from 
mechanical trauma, however this hypothesis lacked evidence (Hermann, 1963).  
Contrary to the thoughts of Erpenstein, (1985) the results of this study showed 
that the structured advice and products provided to the subjects facilitated 
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improvements in plaque control, brought about improvements in the severity of 
the OLP lesions and improved subjects’ oral health related quality of life; the 
intervention did not result in any adverse outcomes and analysis of its cost-
effectiveness has previously been reported (Stone et al., 2013).  
 
Conclusions 
A structured plaque control intervention was effective in improving the oral 
health related quality of life and clinically observed gingival manifestations of 
oral lichen planus.  This study provides evidence to include intensive plaque 
control within patients’ initial and on-going management.  Intensive plaque 
control should, therefore, become an important initial phase of treatment, which 
can be delivered pre-referral by general dentists and dental hygienists.    
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Baseline Week 4 Week 20 
Intervention (SE) 
n=38 
Control (SE)  
n= 41 Difference P-value 
Intervention (SE) 
 n=38 
Control (SE)  
n=40 Difference P-value 
Intervention (SE)  
n=36 
Control (SE)  
n=41 Difference P-value 
Sum OHIP ordinal 49.66 (4.47) 49.39 (4.30) 0.27 0.966 34.62 (2.31) 42.19 (2.25) -7.57 0.022 30.95 (2.81) 42.26 (2.63) -11.31 (3.85) 0.004 
95% CI 40.76, 58.56 40.82, 57.96 -12.09,12.62   30.01, 39.22 37.70, 46.68 -14.00, -1.15   25.35, 36.55 37.02, 47.51 -18.99, -3.64   
Sum OHIP dichotomous 6.55 (0.98) 6.71 (0.95) -0.15 0.910 3.13 (0.51) 5.20 (0.49) -2.07 0.005 2.51 (0.64) 4.94 (0.60) -2.43 0.007 
95% CI 4.59, 8.51 4.82, 8.59 -2.87, 2.57   2.12, 4.14 4.22, 6.18 -3.48, -0.66   1.23, 3.79 3.74, 6.14 -4.19, -0.68   
Functional limitation 10.53 (0.87) 9.80 (0.83) 0.72 0.550 7.71 (0.52) 9.40 (0.50)  -1.69 0.022 6.95 (0.55) 8.85 (0.51) -1.89 0.014 
95% CI 8.80, 12.25 8.14, 11.47 -1.67, 3.12   6.68, 8.74 8.40, 10.40 -3.12, -0.25   5.87, 8.04 7.83, 9.87 -3.39, -0.40   
Physical pain 13.68 (0.88) 14.34 (0.85) -0.66 0.593 9.63 (0.65) 11.38 (0.64)  -1.75 0.059 9.68 (0.77) 11.77 (0.72) -2.09 0.052 
95% CI 11.93, 15.44 12.65, 16.03 -3.10, 1.78   8.33, 10.93 10.11, 12.64 -3.56, 0.07   8.14, 11.22 10.33, 13.21 -4.20, 0.02   
Psychological discomfort 7.79 (0.83) 7.93 (0.80) -0.91 0.905 4.84 (0.48) 6.68 (0.46) -1.84 0.007 4.12 (0.56) 6.63 (0.52) -2.51 0.002 
95% CI 6.14, 9.44 6.34, 9.52 -2.43, 2.16   3.89, 5.79 5.76,7.60 -3.17, 0.52   3.01, 5.23 5.58, 7.67 -4.04, -0.98   
Physical disability 7.97 (0.91) 7.51 (0.88) 0.46 0.716 5.36 (0.57) 7.38 (0.56) -2.03 0.014 4.65 (0.61) 7.18 (0.57) -2.53 0.004 
95% CI 6.16, 9.79 5.76, 9.26 -2.06, 2.98   4.21, 6.50 6.27, 8.50 -3.63, 0.43   3.44, 5.87 6.04,8.32 -4.20, -0.86   
Psychological disability 5.76 (0.79) 5.68 (0.76) 0.08 0.942 3.99 (0.44) 4.48 (0.43) -0.49 0.435 3.21 (0.56) 4.89 (0.53) -1.68 0.032 
95% CI 4.19, 7.33 4.17, 7.20 -2.10, 2.26   3.11, 4.88 3.62, 5.34 -0.17, 0.75   2.08, 4.33 3.84, 5.94 -3.22, -0.15   
Social disability 1.39(0.49) 1.90 (0.47) -0.51 0.458 1.41 (0.24) 1.31 (0.23) 0.10 0.763 1.26 (0.29) 1.16 (0.27) 0.10 0.811 
95% CI 0.42, 2.37 0.96, 2.84 -1.86, 0.85   0.94, 1.89 0.85, 1.77 -0.56, 0.77   0.68, 1.83 0.62, 1.70 -0.69, 0.89   
Handicap 2.53 (0.58) 2.22 (0.56) 0.31 0.705 1.65 (0.29) 1.58 (0.28) 0.07 (0.40) 0.858 1.17 (0.32) 1.70 (0.30) -0.53 0.224 
95% CI 1.37, 3.68 1.11, 3.33 -1.30, 1.91   1.08, 2.22 1.02, 2.14 -0.72, 0.87   0.54, 1.80 1.11, 2.29 -1.39, 0.33   
Table 1.  Sum OHIP scores for ordinal and dichotomous data and Sum OHIP data by domain.  P-values are based on a mixed model F-test (H0=both treatments equal).  
Difference = Mean of treatment difference (intervention – Control). 
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Visit Treatment n Mean (SD) 95% CI p-value 
Week 4 
Intervention 38 1.03 (1.03) 0.86, 1.38 
<0.001 
Control 40 0.26 (0.85) -0.02, 0.53 
Week 20 
Intervention 36 0.94 (1.15) 0.56, 1.33 
0.067 
Control 40 0.44 (1.14) 0.07, 0.81 
Table 2.  Descriptive statistics for global change scores.  Respondents were asked to consider their 
symptoms since the previous visit and indicate if they had improved a lot, improved slightly, stayed 
the same, become slightly worse or become a lot worse.  Positive values indicate treatment 
improvement and negative values indicate deterioration in symptoms.  P-value based on Mann 
Whitney U statistic, as the data were not normally distributed. 
 
Outcome 
measure 
Follow up  Group Mean pre-
treatment (SD) 
Mean post-
treatment 
Effect size 
OHIP-ordinal Week 4 Intervention 49.66 (24.86) 34.55 0.61 
Control 49.39 (29.82) 42.25 0.24 
Week 20 Intervention 49.66 (24.86) 31.64 0.74 
Control 49.39 (29.82) 41.66 0.26 
OHIP-
dichotomous 
Week 4 Intervention 6.55 (4.91) 3.03 0.72 
Control 6.71 (6.97) 5.30 0.20 
Week 20 Intervention 6.55 (4.91) 2.56 0.74 
Control 6.71 (6.97) 4.90 0.26 
Pain (VAS) Week 4 Intervention 3.34 (2.07) 2.27 0.52 
Control 3.36 (2.23) 2.95 0.18 
Week 20  Intervention 3.34 (2.07) 1.85 0.70 
Control 3.36 (2.23) 2.49 0.38 
Plaque Index Week 4 Intervention 1.42 (0.36) 0.89 1.47 
Control 1.45 (0.34) 1.44 0.03 
Week 20 Intervention 1.42 (0.36) 0.86 1.56 
Control 1.45 (0.34) 1.47 -0.06 
Escudier oro-
mucosal 
disease index 
Week 4 Intervention 31.12 (9.62) 23.93 0.75 
Control 27.97 (8.07) 28.46 -0.06 
Week 20 Intervention 31.12 (9.62) 21.40 1.01 
Control 27.97 (8.07) 25.65 0.29 
Table 3.  Unadjusted mean pre- and post-treatment values, standard deviations and Cohen’s d effect 
sizes.  It is generally accepted that d values of 0.2 represent small change, 0.5 represent moderate 
change and those >0.8 represent large change.  Negative values represent deterioration from 
baseline. 
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